苯达莫司汀联合利妥昔单抗作为适合及不适合移植的套细胞淋巴瘤患者的诱导治疗
自2013年6月起,加拿大不列颠哥伦比亚省190例成人套细胞淋巴瘤患者接受苯达莫司汀联合利妥昔单抗(BR)诱导治疗,总缓解率88%(完全缓解54%)。与历史队列248例R-CHOP治疗患者相比,BR组无进展生存期显著改善,但总生存期无显著差异;高危特征患者结局欠佳,需进一步研究整合新药。
要点
- BR诱导治疗套细胞淋巴瘤总缓解率88%,完全缓解率54%。
- 全队列3年无进展生存率BR组66% vs R-CHOP组51%,差异有统计学意义。
- 高危特征(MIPI高危、Ki-67≥50%、母细胞样/多形性组织学)患者结局欠佳。
核心结论
- BR是大多数套细胞淋巴瘤患者有效的 first-line 选择,但高危特征患者结局欠佳,需进一步研究整合新药。
研究设计与样本
- 自2013年6月起,加拿大不列颠哥伦比亚省190例≥18岁套细胞淋巴瘤患者接受BR治疗,并与2003年1月至2013年5月接受R-CHOP治疗的248例历史队列比较。
主要发现
- BR总缓解率88%,完全缓解率54%;89例≤65岁患者中61例(69%)接受自体干细胞移植,全队列190例中141例(74%)接受利妥昔单抗维持治疗。
- 23例(12%)出现疾病进展,与MIPI高危、Ki-67≥50%及母细胞样/多形性组织学相关。
- 全队列3年无进展生存率BR组66% vs R-CHOP组51%(P=0.003),3年总生存率BR组73% vs R-CHOP组66%(P=0.054)。
- 65岁以上患者3年无进展生存率BR组56% vs R-CHOP组35%(P=0.001),3年总生存率BR组64% vs R-CHOP组55%(P=0.063)。
- 移植患者中BR组与R-CHOP组3年无进展生存率85% vs 76%(P=0.135),3年总生存率90% vs 88%(P=0.305),差异无统计学意义;多因素分析中BR与无进展生存期改善相关(风险比0.40,95%置信区间0.17-0.94,P=0.036),总生存期无显著改善。
临床怎么用
- 作者认为BR是大多数套细胞淋巴瘤患者有效的 first-line 选择,但高危特征患者结局欠佳,需进一步研究整合新药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rituximab-containing chemotherapy regimens constitute standard first-line therapy for mantle cell lymphoma (MCL). Since June 2013, 190 patients ≥18 years of age with MCL in British Columbia have been treated with bendamustine and rituximab (BR). The overall response rate to BR was 88% (54% complete response). Of these, 61 of 89 patients (69%) aged ≤65 years received autologous stem cell transplantation and 141 of 190 patients (74%) from the entire cohort received maintenance rituximab. Twenty-three patients (12%) had progressive disease, associated with high risk per the Mantle Cell Lymphoma International Prognostic Index (MIPI), Ki-67 ≥50%, and blastoid/pleomorphic histology. Outcomes were compared with a historical cohort of 248 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; January 2003 to May 2013). Treatment with BR was associated with significant improvements in progression-free survival (PFS), but not overall survival (OS), compared with R-CHOP in the whole cohort (3-year PFS, 66% BR vs 51% R-CHOP, P = .003; 3-year OS, 73% BR vs 66% R-CHOP, P = .054) and in those >65 years of age (3-year PFS, 56% BR vs 35% R-CHOP, P = .001; 3-year OS, 64% BR vs 55% R-CHOP, P = .063). Outcomes in transplanted patients were not statistically significantly different compared with R-CHOP (3-year PFS, 85% BR vs 76% R-CHOP, P = .135; 3-year OS, 90% BR vs 88% R-CHOP, P = .305), although in multivariate analyses, treatment with BR was associated with improved PFS (hazard ratio, 0.40 [95% confidence interval, 0.17-0.94]; P = .036) but not OS. BR is an effective first-line option for most patients with MCL, however, outcomes are suboptimal for those with high-risk features and further studies integrating novel agents are warranted.
引用
- Villa D, Sehn LH, Savage KJ, et al. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2020. PMID: 32735654. doi:10.1182/bloodadvances.2020002068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。